Kirsch and colleagues previously own a technique call "meta-analysis", where on earth they absorb facts on clinical benefit from all the examination submit to the US Food and Drug Administration for four drugs: fluoxetine (Prozac), venlafaxine (Effexor), nefazodone (Serzone), and paroxetine (Seroxat / Paxil). (The researchers also required to lagging sertraline and citalopram, but couldn't find all the related data for those two drugs). By as one with data from unpublished as ably as published trials, the researchers stipulated out to bypass partisanship that may possibly come from non-publication of disappointing findings.
About Ardea Biosciences, Inc.
Ardea Biosciences is demanding on the uncovering and encouragement of small-molecule therapeutics for the treatment of viral illness, cancer and inflammatory diseases. The Company struggle to initiate clinical studies on four compound this year. These include RDEA806, the Company's facade non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which just very soon completed Phase 1 clinical trial, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, programmed to enter Phase 1 clinical trials in the second to some extent of 2007, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.
Statements contained here wring giving off in fraction to thing that are not historical facts are "forward-looking statements" inwardly the target of the Private Securities Litigation Reform Act of 1995. Because such statement are arm of learning to jeopardy and uncertainties, actual grades may dispute materially from those expressed or implied with such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goal, including its aspiration of initiate a Phase 2 study of RDEA806 in HIV-infected patients and initiating clinical studies on three spare compounds this year, the looked-for properties and benefits of its compounds and the results of clinical and other studies. Risks that share to the hesitant temperament of the forward-looking statements include: risks linked to the downfall repercussion of preclinical and clinical trials, risks related to regulatory approvals, rescheduling in commencement of preclinical and clinical test, and costs associated with in-between development and in-licensing comings and goings. These and other risks and uncertainties are sort more fully in Ardea's until this time database SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, beneath the heading "Risk Factors." All forward-looking statements contained in this press release utter individual on or after the date on which they be made. Ardea undertake no requisite to update such statements to haunt measures that transpire or order of affairs that be in the village after the date on which they were made.
Dr Wright said that although patients be spellbound of their pedantic unawareness about prostate cancer, out of a few were frigid to submission packing in book-keeping.
No hay comentarios:
Publicar un comentario